OPTIMIZED Fc VARIANTS
AssigneeXencor, Inc.
InventorsGregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
Life of this patent
Estimating the term…
Abstract
The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Claims18
1-8. (canceled)
A method comprising administering to a patient a polypeptide comprising a variant Fc region comprising an amino acid substitution at position 271 of the Fc region as compared to a parent Fc region, wherein said variant Fc region exhibits enhanced binding affinity to FcγRIIb as compared with the parent Fc region, wherein numbering is according to the EU index.
A method comprising administering to a patient a polypeptide comprising a variant Fc region comprising an amino acid substitution at position 271 of the Fc region as compared to a parent Fc region, wherein the amino acid substitution is glycine, wherein said variant Fc region exhibits enhanced binding affinity to FcγRIIb as compared with the parent Fc region, wherein numbering is according to the EU index.
A nucleic acid encoding a polypeptide comprising a variant Fc region comprising an amino acid substitution at position 271 of the Fc region as compared to a parent Fc region, wherein said variant Fc region exhibits enhanced binding affinity to FcγRIIb as compared with the parent Fc region, wherein numbering is according to the EU index.
Dependencies are inferred from the claim text.